This study focuses on patients with urothelial carcinoma, a type of cancer that affects the lining of the urinary system, including the bladder, urethra, ureters, and renal pelvis. The study will test a medication called disitamab vedotin, which will be given either alone or in combination with another medication called pembrolizumab. The study specifically looks at cases where the cancer is either locally advanced (cannot be surgically removed) or has spread to other parts of the body (metastatic), and where the cancer cells show a specific protein marker called HER2.

The purpose of this research is to determine how well disitamab vedotin works in treating urothelial carcinoma, both when used alone and when combined with pembrolizumab. The medication will be given through an intravenous infusion, which means it is delivered directly into a vein. The maximum dose that may be given is 1.5 milligrams per kilogram of body weight, up to 150 milligrams total.

During the study, participants will receive regular medical examinations and scans to monitor their response to treatment. The study is designed for patients who have previously received treatment for their cancer, as well as those who have not yet received any treatment. Participants will be monitored for any side effects throughout their participation in the study.